Wednesday, April 17, 2024 4/17/2024

Mesenchymal Stem Cell Exosome in Efferocytosis of Apoptotic Cardiomyocytes and Repair after Myocardial Ischemia

Award Number: R01HL138023
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By Issue Date FY or Funding FY:

View Award Abstract

Summary Cardiovascular diseases like myocardial infarction (MI) are the leading cause of mortality in patients with diabetes. In infarcted heart, efficient clearance of dying cells (called efferocytosis) by activated neighboring phagocytes (primarily infiltrating macrophages) is essential for inflammation resolution and tissue repair. However, improper clearance of dying cells leads to secondary postapoptotic necrosis and therefore may precipitate the transition to heart failure. Our preliminary study demonstrates that diabetic condition impairs efferocytosis of dead cardiomyocytes by macrophages, in vitro and in human diabetic heart as compared to non-diabetics. However, the molecular players in diabetes-mediated defective efferocytosis and its effect on cardiac remodeling and outcome are surprisingly not studied yet. Therefore, studying the mechanisms of diabetes-mediated impairment in efferocytosis of dead cells (specifically cardiomyocytes) and strategies to enhance resolution of inflammation leading to efficient cardiac healing and recovery are clinically relevant and therapeutically novel. In this regard, therapy with paracrine factors (exosomes) from mesenchymal stem cells (MSC), a potent immunomodulator and clinically tested for safety and efficacy in ischemic heart failure patients, holds great promise. However, the effect of MSC and its derivatives on macrophage efferocytosis of cardiomyocytes either with or without diabetes in a small/larger animal model of MI has never been studied so far. Our preliminary data shows that MSC- derived exosomes increase macrophage efferocytosis of dead cardiomyocytes, in vitro. Based on these preliminary data coupled with our published and existing literature, our central hypothesis is that i) diabetes impairs macrophage efferocytosis of dead cardiomyocytes leading to delay in resolution of inflammation and cardiac repair in diabetics, ii) MSC-derived exosomes are enriched in factors (RNA/miRNA/proteins) that promote efferocytosis, therefore iii) intramyocardial delivery of MSC- derived exosomes in a small/large animal model of MI enhances efferocytosis and wound healing leading to efficient regeneration and repair. We will test our hypotheses under the following three aims: Aim 1: Determine the effect of diabetes on clearance of dead cardiomyocyte (efferocytosis) after myocardial ischemic injury. Aim 2: Elucidate the molecular mechanism of MSC-exosome effect on macrophage-mediated efferocytosis. Aim 3: a. Delineate the invivo effect of MSC-exosome on efferocytosis after myocardial infarction a) in mice and b) in a translationally realistic large animal (pig) model of heart failure.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2023 ( Subtotal = -$1,627 )
2023	2021	UNIVERSITY OF ALABAMA AT BIRMINGHAM	701 S 20TH STREET	BIRMINGHAM	AL	35294	JEFFERSON	USA	Cardiovascular Diseases Research	000	4	9/26/2023	NON-COMPETING CONTINUATION	-$1,627
														Subtotal = -$1,627

Issue Date FY: 2021 ( Subtotal = $660,745 )
2021	2021	UNIVERSITY OF ALABAMA AT BIRMINGHAM	701 S 20TH ST	BIRMINGHAM	AL	35294	JEFFERSON	USA	Cardiovascular Diseases Research	000	4	12/21/2020	NON-COMPETING CONTINUATION	$594,671
2021	2021	UNIVERSITY OF ALABAMA AT BIRMINGHAM	701 S 20TH ST	BIRMINGHAM	AL	35294	JEFFERSON	USA	Cardiovascular Diseases Research	001	4	5/18/2021	NON-COMPETING CONTINUATION	$66,074
														Subtotal = $660,745

Issue Date FY: 2020 ( Subtotal = $660,745 )
2020	2020	UNIVERSITY OF ALABAMA AT BIRMINGHAM	701 S 20TH ST	BIRMINGHAM	AL	35294	JEFFERSON	USA	Cardiovascular Diseases Research	001	3	1/25/2020	NON-COMPETING CONTINUATION	$33,039
2020	2020	UNIVERSITY OF ALABAMA AT BIRMINGHAM	701 S 20TH ST	BIRMINGHAM	AL	35294	JEFFERSON	USA	Cardiovascular Diseases Research	000	3	12/11/2019	NON-COMPETING CONTINUATION	$627,706
														Subtotal = $660,745

Issue Date FY: 2019 ( Subtotal = $660,745 )
2019	2019	UNIVERSITY OF ALABAMA AT BIRMINGHAM	701 S 20TH ST	BIRMINGHAM	AL	35294	JEFFERSON	USA	Cardiovascular Diseases Research	000	2	12/12/2018	NON-COMPETING CONTINUATION	$660,745
														Subtotal = $660,745

Issue Date FY: 2018 ( Subtotal = $660,745 )
2018	2018	UNIVERSITY OF ALABAMA AT BIRMINGHAM	701 S 20TH ST	BIRMINGHAM	AL	35294	JEFFERSON	USA	Cardiovascular Diseases Research	000	1	12/7/2017	NEW	$660,745
														Subtotal = $660,745

Grand Total All Awards = $2,641,353

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Mesenchymal Stem Cell Exosome in Efferocytosis of Apoptotic Cardiomyocytes and Repair after Myocardial Ischemia

Award Number: R01HL138023

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer